FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 564 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby November 25, 2020 Searching for novel connections in cancer metabolism June 19, 2020 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... July 12, 2021 Load more HOT NEWS Study Offers Insights on Health Problems among AYA Cancer Survivors Life beyond cancer: Improving the long term side effects for children... Few People with Cancer Undergo Testing for Inherited Gene Mutations How Joining a Clinical Trial Helped Me Find Hope While Living...
